In order to elucidate the predictive power of circulating tumor cells, Lucci and colleagues studied 243 stage III-node-positive melanoma patients using the CellSearchTM Circulating Melanoma Cell assay based on a single enrichment marker, the anti-CD146 antibodies, along with anti-CD45 and anti-CD34 to exclude lymphocytes and endothelial cells, respectively [40]. Here, MCAM is linked to melanoma.